Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Moodys
McKinsey
Dow
Johnson and Johnson

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,518,111

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,518,111
Title:Compositions comprising a p75 tumor necrosis factor receptor/Ig fusion protein
Abstract: The present invention relates to pharmaceutical compositions comprising a p75 tumor necrosis factor receptor/Ig fusion protein.
Inventor(s): Gombotz; Wayne Richard (Kenmore, WA), Remmele, Jr.; Richard L. (Clarksburg, MD)
Assignee: Immunex Corporation (Thousand Oaks, CA)
Application Number:14/478,926
Patent Claims:1. A pharmaceutical composition comprising a polypeptide that is an extracellular ligand-binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of a human IgG1 and from about 10 mM to about 200 mM L-arginine.

2. The pharmaceutical composition of claim 1, wherein the composition is in a liquid state.

3. The pharmaceutical composition of claim 2, wherein the composition is in a pre-filled sterile syringe.

4. The pharmaceutical composition of claim 1, further comprising a buffer.

5. The pharmaceutical composition of claim 4, wherein the buffer is selected from the group consisting of sodium phosphate, histidine, potassium phosphate, sodium citrate, potassium citrate, maleic acid, ammonium acetate, tris-(hydroxymethyl)-aminomethane (tris), acetate and diethanolamine.

6. The pharmaceutical composition of claim 1, further comprising a tonicity modifier.

7. The pharmaceutical composition of claim 6, wherein the tonicity modifier is selected from the group consisting of arginine, cysteine, histidine, glycine, sodium chloride, potassium chloride, sodium citrate, sucrose, glucose and mannitol.

8. The pharmaceutical composition of claim 7, wherein the tonicity modifier is sodium chloride.

9. The pharmaceutical composition of claim 1, further comprising an excipient.

10. The pharmaceutical composition of claim 7, further comprising an excipient.

11. The pharmaceutical composition of claim 9, wherein the excipient is selected from the group consisting of sucrose, lactose, glycerol, xylitol, sorbitol, Mannitol, maltose, inositol, trehalose, glucose, bovine serum albumin (BSA), human SA or recombinant HA, dextran, PVA, hydroxypropyl methylcellulose (HPMC), polyethyleneimine, gelatin, polyvinylpyrrolidone (PVP), hydroxyethylcellulose (HEC), polyethylene glycol, ethylene glycol, glycerol, dimethysulfoxide (DMSO), dimethylformamide (DMF), proline, L-serine, sodium glutamic acid, alanine, glycine, lysine hydrochloride, sarcosine, gamma-aminobutyric acid, polysorbate-20, polysorbate-80, SDS, polysorbate, polyoxyethylene copolymer, potassium phosphate, sodium acetate, ammonium sulfate, magnesium sulfate, sodium sulfate, trimethylamine N-oxide, betaine, zinc ions, copper ions, calcium ions, manganese ions, magnesium ions, CHAPS, sucrose monolaurate, and 2-O-beta-mannoglycerate.

12. The pharmaceutical composition of claim 11, wherein the excipient is sucrose.

13. A pharmaceutical composition comprising about 10 mg/ml to about 100 mg/ml of a polypeptide that is an extracellular ligand-binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of a human IgG1, about 10 mM to about 200 mM L-arginine, and sodium phosphate, sodium chloride and sucrose.

14. The pharmaceutical composition of claim 13, wherein the L-arginine is at about 10 mM to about 75 mM.

15. The pharmaceutical composition of claim 13, wherein the sodium phosphate is at about 5 mM to about 100 mM.

16. The pharmaceutical composition of claim 13, wherein the sucrose is at about 0.5% to about 1.5%.

17. The pharmaceutical composition of claim 13, wherein the pH is about 5.5 to about 7.8.

18. The pharmaceutical composition of claim 13, having about 50 mg/ml of the polypeptide that is an extracellular ligand-binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of a human IgG1, about 25 mM L-arginine, about 25 mM sodium phosphate, about 98 mM sodium chloride, about 1% sucrose, and wherein the composition is about pH 6.2.

19. The pharmaceutical composition of claim 1, wherein the polypeptide is etanercept.

20. The pharmaceutical composition of claim 4, wherein the polypeptide is etanercept.

21. The pharmaceutical composition of claim 6, wherein the polypeptide is etanercept.

22. The pharmaceutical composition of claim 9, wherein the polypeptide is etanercept.

23. The pharmaceutical composition of claim 13, wherein the polypeptide is etanercept.

Details for Patent 9,518,111

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Thousand Oaks, CA) 2022-02-27 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial Immunex Corporation (Thousand Oaks, CA) 2022-02-27 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Dow
Johnson and Johnson
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.